- Sesen Bio is seeking an accelerated approval for its NMIBC therapy, Vicineum, and the PDUFA date is coming up soon on Aug. 18.
- Vicineum looks to fill a large need for additional pre-cystectomy therapies in patients who have already tried BCG therapy, and Sesen already inked two partnerships overseas.
- Sesen looks meaningfully undervalued at present which suggests that we could see a run-up ahead of the PDUFA but also that the company could trade higher long term as well.
For further details see:
Sesen Bio: Long-Term And Short-Term Potential In Advance Of Its First PDUFA